<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117689</url>
  </required_header>
  <id_info>
    <org_study_id>Thymo102700103</org_study_id>
    <nct_id>NCT00117689</nct_id>
  </id_info>
  <brief_title>Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection</brief_title>
  <official_title>A Randomized, Controlled, Multi-Center Study of Thymoglobulin Induction Therapy With a Calcineurin Inhibitor Sparing Regimen in Liver Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This study involves the use of a drug called Thymoglobulin, which is approved in the US to
      treat kidney transplant rejection and in Canada to treat and prevent kidney transplant
      rejection. This study will evaluate the effect of Thymoglobulin induction therapy and reduced
      doses of calcineurin inhibitors on the incidence of liver rejection and will provide a basis
      for future evaluations of Thymoglobulin as an immunosuppressive agent to help decrease the
      incidence of liver transplant rejection. Subjects meeting all inclusion and exclusion
      criteria are eligible to participate in this study. Approximately 75 study subjects from up
      to 18 transplant centers in the United States and Canada will be enrolled in this 12-month
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from biopsy-proven acute rejection (including humoral rejection)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore the impact of Thymoglobulin on kidney function after transplant</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the impact of Thymoglobulin on the prevention of liver transplant rejection, transplanted liver loss, death, and safety of Thymoglobulin after transplant.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Liver Dysfunction</condition>
  <condition>Rejection, Transplant</condition>
  <condition>Transplantation, Liver</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard (tacrolimus based standard therapy without induction)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>[Anti-thymocyte Globulin (rabbit)]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>For a minimum of 3 months</description>
    <arm_group_label>2 Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Between Day 3 the last dose of Thymoglobulin</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2 Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>for at least 1 month posttransplant</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2 Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary liver transplant recipient with Model for End-Stage Liver Disease (MELD)
             criteria documentation

          -  Serum creatinine &gt; 1.5mg/dL at the time of transplant, or based on the value used to
             calculate the most recent pre-operative MELD Score for liver allocation

          -  Ages greater than or equal to 18 years

          -  If female, must not be lactating; must have a negative serum beta-human chorionic
             gonadotropin (HCG) test within 7 days prior to Study Day 0 (Day of Transplant); and
             must agree to practice an acceptable and reliable form of contraception during the
             study

          -  Signed informed consent

        Exclusion Criteria:

          -  Living donor or multiple organ transplants

          -  Prior solid organ or bone marrow transplant recipient

          -  Fulminant hepatic failure

          -  Status 1 transplants

          -  ABO incompatible transplants

          -  Transplants utilizing livers from non heart-beating donors

          -  Liver transplant candidates with &gt; 6 weeks of analysis

          -  Donor with positive serology for hepatitis B surface antigen (HBsAg)

          -  Evidence of human immunodeficiency virus (HIV)

          -  Autoimmune hepatitis

          -  History of chronic steroid or immunosuppressant use in the 90 days prior to
             transplant, except for inhaled corticosteroids to treat asthma

          -  Recipient of investigational therapy within 90 days prior to transplant procedure

          -  Known contraindication to administration of rabbit anti-thymocyte globulin

          -  Acute viral illness

          -  History of malignancy within 5 years, with the exception of adequately treated
             localized squamous or basal cell carcinoma of the skin without evidence of recurrence,
             and/or hepatocellular carcinoma

          -  Illness other than primary liver disease (e.g. severe ischemic heart disease, left
             ventricular dysfunction, or pulmonary disease), which, in the opinion of the
             investigator, may significantly increase the risk of the transplantation procedure

          -  Current drug and alcohol abuse that, in the opinion of the investigator, puts subjects
             at risk for poor compliance (no drug test required)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC University Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Fransisco Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital and Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview University Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio, University Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCU Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto University Hospital - UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2005</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-T cell antibodies</keyword>
  <keyword>Primary Liver Transplantation and Renal Dysfunction</keyword>
  <keyword>Liver Transplant Rejection</keyword>
  <keyword>Induction Therapy with reduction of Calcineurin inhibitors</keyword>
  <keyword>Primary Liver Transplantation</keyword>
  <keyword>Primary Transplant Rejection</keyword>
  <keyword>Transplantation, Liver</keyword>
  <keyword>Rejection, Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

